GeneDx Holdings Corp. (WGS) Q3 Earnings and Revenues Surpass Estimates

Core Insights - GeneDx Holdings Corp. reported quarterly earnings of $0.49 per share, exceeding the Zacks Consensus Estimate of $0.28 per share, and showing a significant increase from $0.04 per share a year ago, resulting in an earnings surprise of +75.00% [1] - The company achieved revenues of $116.74 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 12.47% and increasing from $76.87 million year-over-year [2] - GeneDx Holdings has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $0.51 on revenues of $116.5 million, and for the current fiscal year, it is $1.56 on revenues of $410.1 million [7] Industry Context - The Medical Services industry, to which GeneDx Holdings belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]